What topics does this cannabis study cover?

This study covers research on: Sleep, Pain, Anxiety, Inflammation.

Where was this research published?

Published in Journal of psychoactive drugs on September 15, 2026.

Survey links CBG use with perceived improvements in sleep and pain

Q: What did this research study find?

In this survey of **239 *CBG/CBGA* users**, the most frequently reported target was insomnia or disturbed sleep (**62%**), followed by inflammatory chronic pain (**44%**) and anxiety (**33%**).

A Survey of Cannabigerol User's Patterns of Use, Perceived Efficacy and Satisfaction.

Journal of psychoactive drugs • September 15, 2026 • Highly Relevant

🤖

AI Summary

This observational survey examined how 239 people who used CBG or CBGA used these cannabinoids, which conditions they were trying to manage, and how effective and satisfying they believed them to be. The most commonly reported uses were insomnia or disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%). Participants generally said CBG/CBGA slightly to much improved their symptoms, but these were self-reported perceptions rather than objectively measured treatment effects.

Participants reported typically using 10–12 mg of CBG and said effects began within 15–60 minutes after oral ingestion and lasted 4–6 hours. Because this was a survey without a comparison group, it cannot determine whether CBG/CBGA caused the reported improvements, establish clinical effectiveness, or show how the compounds compare with other treatments. This is an abstract-based summary; the most consequential limitation is the reliance on users’ own reports rather than controlled clinical assessments.

💡 Key Findings

In this survey of 239 CBG/CBGA users, the most frequently reported target was insomnia or disturbed sleep (62%), followed by inflammatory chronic pain (44%) and anxiety (33%).

High

90%

Participants generally reported that CBG/CBGA slightly to much improved their symptoms, but this was a perceived effect from an observational survey and does not establish causation or clinical efficacy.

High

80%

Users reported a typical CBG dose of 10–12 mg, with effects perceived within 15–60 minutes of oral ingestion and lasting 4–6 hours.

High

90%

The survey can help guide future human research, but its self-reported design and lack of a comparator mean it cannot determine whether CBG/CBGA caused the reported benefits.

High

90%

📄 Original Abstract

Cannabigerol (CBG) and the acidic form of CBG (cannabigerolic acid, CBGA) are becoming increasingly more available and popular, with pre-clinical rodent research suggesting these compounds have an array of therapeutic effects. However, there have been few clinical trials or surveys examining their effects in humans. We conducted a survey of 239 CBG/CBGA users to assess the medical conditions they use CBG/CBGA to manage, as well as their perceived efficacy and satisfaction with CBG/CBGA for managing these conditions. Participants also reported on their typical use patterns (e.g. typical dose), their perceived time to feel effects, and duration of those effects. The top five conditions participants reported using CBG/CBGA to manage were insomnia/disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%), with participants generally reporting that CBG/CBGA "slightly improves" to "much improves" their symptoms. Participants reported typically using a dose of 10-12 mg of CBG and they indicated that they feel effects within 15-60 min of oral ingestion and that these effects persist for 4-6 h. These findings will help inform consumers of CBG as well as researchers designing clinical trials to investigate the effects of CBG on humans in a more objective manner.

Paper Type

📄 Research

Publication

Journal: Journal of psychoactive drugs
Published: September 15, 2026
PMID: 42741890
DOI: 10.1080/02791072.2026.2727651

Authors (5)

Erika T H Lutz Department of Psychology, Washington State University, Pullman, WA, USA.
Dustin Sulak Healer Hemp, Brunswick, ME, USA.
Leigh Vinocur Ananda Medical Practice and Consulting, Owings Mills, MD, USA.
Ethan B Russo CReDO Science, Vashon, WA, USA.
Carrie Cuttler Department of Psychology, Washington State University, Pullman, WA, USA.